The company said that BL-5010 is a convenient treatment that offers an alternative to painful, invasive and expensive removal treatments such as surgery, cryotherapy or laser treatment. Because the treatment is non-invasive, it poses minimal infection risk and no need for anesthesia or bandaging.
BL-5010 is applied topically on the lesion for a few minutes, and causes the lesion to gradually dry out and shed from the skin within one to three weeks. BL-5010 also preserves the cellular structure of the lesion, enabling histological examination.
Morris Laster, CEO of BioLineRx, said: “BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions. We look forward to accelerating development of this novel formulation.”